Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.

Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.

Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.

Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.

Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.

Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.